In patients with chronic GvHD, Matsuoka and co-workers reported that daily administration of low-dose IL-2 induced selective expansion of functional CD4+CD25+CD127− Tregs, improved chronic GvHD, restored CD4+ T cell homeostasis, and promoted the reestablishment of immune tolerance (87). This evidence concerns the gene IL2 and graft versus host disease.